Inactive Instrument
Cerevel Therapeutics Holdings, Inc. Share Price
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
| 1 day | +0.74% |
| 3 years | 21.86 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/05/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 20/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 20/01/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/08/24 | Issuer sale | Chief Medical Officer | 14,95,399 | 0.8208% | ||
| 01/08/24 | Issuer sale | Director | 1,08,985 | 0.0598% | ||
| 01/08/24 | Issuer sale | Director | 1,37,525 | 0.0755% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | - | - | 819.15Cr | |
| +0.79% | -6.16% | +49.32% | +74.50% | 6.63TCr | |
| +1.92% | +10.35% | +13.02% | +87.74% | 5.29TCr | |
| +6.91% | +8.57% | +6.88% | +72.12% | 5.48TCr | |
| +0.74% | +2.75% | +26.31% | +45.29% | 4.41TCr | |
| +3.87% | +10.15% | +20.69% | +132.73% | 4.37TCr | |
| +7.91% | +4.30% | +263.91% | +602.72% | 4.21TCr | |
| -0.40% | +9.85% | +17.04% | +59.17% | 3.4TCr | |
| +0.10% | +0.72% | +39.09% | +8.56% | 2.62TCr | |
| +2.36% | +5.34% | +30.98% | +26.07% | 2.34TCr | |
| Average | +2.49% | +1.67% | +51.92% | +123.21% | 4.31TCr | |
| Weighted average by Cap. | +2.83% | +1.99% | +51.21% | +127.93% |
Employees
355
